A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma

European Journal of Cancer Part A

Volumn 33, Issue 9, 1997, Pages 1373-1379

  Messori, A ^a   Becagli, P ^a   Trippoli, S ^a   Tendi, E ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cost effectiveness; Interferon; Melanoma; Pharmacoeconomics

Indexed keywords

INTERFERON;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; INTERFERON ALFA-2B; MELANOMA; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0030853798     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00413-3     Document Type: Article

References (27)

1. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995, 332, 1418-1424.
2. Mark DB. Economic analysis methods and end-points. In Califf RM, Mark DB, Wagner B, eds. Acute Coronary Care in The Thrombolytic Era. St. Louis, Mosby, 1995, 167-182.
3. Wong JB, Koff RS, Tinh F, Pauker SG. Cost-effectiveness of interferon-alpha2b treatment for hepatitis B-e-antigen-positive chronic hepatitis B. Ann Intern Med 1995, 122, 664-675.
4. Messori A, Becagli P, Trippoli S, Tendi E. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 1996, 51, 111-116.
5. Messori A, Bonistalli L, Costantini M, Trallori G, Tendi E. Cost-effectiveness of adjuvant intraportal supportive therapy in colorectal cancer. J Clin Gastroenterol 1996, 23, 269-274.
6. Etchanson J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995, 332, 719-724.
7. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991, 325, 81-86.
8. Welch HG, Larson EB. Cost-effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989, 321, 807-812.
9. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TH, Borden EC, Blum RH. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14, 7-17.
10. Cascinelli N. Evaluation of efficacy of adjuvant rIFN-alpha-2a in melanoma patients with regional metastasis (Abstract). Proc Am Soc Clin Oncol 1995, 14, 410.
11. Cascinelli N, Bufalino R, Morabito A, et al. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994, 343, 913-914.
12. Creagan E, Dalton R, Ahmann D, et al. Randomised surgical adjuvant clinical trial of recombinant interferon alpha-2a in selected patients with malignant melanoma. 3 Clin Oncol 1995, 13, 2776-2783.
13. Balch CM, Buzaid AC. Finally, a successful adjuvant therapy for high-risk melanoma. J Clin Oncol 1994, 14, 1-3.
14. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996, 334, 835-840.
15. Lee ET. Statistical Methods for Survival Data Analysis. Belmont, CA, Lifetime Learning, 1980.
16. Varoli G. Matematica Finanziaria. Patron, Bologna, 1990.
17. Messori A. Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data. Comput Meth Progr Biomed 1997, 52, 157-164.
18. Robinson R. Cost-effectiveness analysis. BMJ 1993, 307, 793-795.
19. Coyle D. Statistical analysis in pharmacoeconomic studies - a review of current issues and standards. Pharmacoeconomics 1966, 6, 506-516; see enclosed photocopies, summarises the current methodological trends in this area.
20. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990, 82, 1106-1116.
21. Messori A, Rampazzo R. Meta-analysis of clinical trials based on censored end-points: simplified theory and implementation of the statistical algorithms on a microcomputer. Comput Progr Meth Biomed 1993, 40, 261-267.
22. Gerber RD, Goldhirsch A, Cavalli F. Quality-of-life adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 1991, 114, 621-628.
23. Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus infection. Ann Intern Med 1991, 114, 798-802.
24. Goldman L, Sia STB, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988, 319, 152-157.
25. Brown ML, Nayfiled SG, Shibley LM. Adjuvant therapy for Stage III colon cancer: economic returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 1994, 86, 424-430.
26. Messori A. Trends, new developments and pharmacoeconomics. EHP 1996, 2, 124-127.
27. Uyl-de Groot CA, Hagenbeek A, Verdonk LF, Lowenberg B, Rutten FF. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate and high-grade malignant non-Hodgkin lymphoma. Bone Marrow Transpl 1995, 16, 463-470.